Astria Therapeutics, Inc., a biopharmaceutical company specializing in therapies for allergic and immunologic diseases, has entered into a licensing agreement with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of navenibart in Japan. Navenibart is a long-acting investigational monoclonal antibody inhibitor of plasma kallikrein, currently in Phase 3 development for the preventative treatment of hereditary angioedema $(HAE)$. Under the agreement, Astria will receive an upfront payment of $16 million, with potential additional commercialization and sales milestones totaling $16 million. The company is also eligible for tiered royalties based on net sales, reaching up to 30%, and will receive partial reimbursement for Phase 3 costs. Kaken will support the ALPHA-ORBIT Phase 3 trial, handle regulatory submissions in Japan, and share in the costs of the Phase 3 program. No results from the Phase 3 trial have been presented as of the announcement.